文献速递银屑病与炎症性皮肤病

VISIBLE试验:提升银屑病研究多样性的质量改进框架

Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement.
PubMed 文献 · JAMA Dermatol · 2025-01-01

VISIBLE试验为一项针对肤色人群(SoC)中重度斑块状银屑病的随机临床试验,评估古塞奇尤单抗治疗,并采用多种创新策略招募和保留多样化参与者。2022年8月至2023年3月共入组211例,入组速度约为预期的7倍,全部参与者自报为非白人种族或族裔。该研究旨在填补肤色人群银屑病临床反应、遗传学和生活质量等方面的数据缺口。

要点

  • 采用客观色度计与自我报告种族/族裔相结合的策略,扩大肤色人群入选范围。
  • 多样化现场选择、文化能力培训及患者母语报告结局等创新措施促进招募与保留。
  • 入组速度约为预期的7倍,超过50%参与者Fitzpatrick皮肤类型为IV-VI型。

核心结论

  • VISIBLE试验通过有意且策略性的设计,可加速多样化人群的招募并提升参与和保留。
  • 该研究旨在为肤色银屑病人群的临床 care 和皮肤科研究多样性最佳实践提供数据。

研究设计与样本

  • VISIBLE试验的事后质量改进评估,评估招募和保留多样化参与者的方法。
  • 2022年8月至2023年3月入组并随机211例肤色中重度斑块状银屑病参与者,平均(SD)年龄43(13)岁,女性75例(36%),男性136例(64%)。

主要发现

  • 入组速度约为预期的7倍(对比银屑病研究历史招募数据)。
  • 211例参与者(100%)自报为非白人种族或族裔。
  • 超过50%参与者皮肤色调位于Fitzpatrick皮肤类型谱的较深半区(IV-VI型)。

关键数值与推荐

  • 参与者自报种族和族裔:美洲印第安人/阿拉斯加原住民1例(0.5%)、亚裔63例(29.9%)、黑人24例(11.4%)、西班牙裔/拉丁裔94例(44.5%)、中东裔13例(6.2%)、太平洋岛民/夏威夷原住民1例(0.5%)、多种族12例(5.7%)、其他种族和/或族裔3例(1.4%)。
  • 使用色度计确定Fitzpatrick皮肤类型与自我报告种族和族裔(符合SoC)相结合来拓宽入选。
  • 创新措施包括:评估炎症后色素改变自然史、评估遗传和合并症生物标志物、多样化现场选择、文化能力培训、母语患者报告结局采集、盲态中心疗效评分反馈。

临床怎么用

  • 在皮肤科临床试验中采用多样化现场选择、文化能力培训和母语结局采集可提升少数族裔参与。
  • 结合客观色度计与自我报告标准有助于准确识别肤色人群并扩大入选范围。
  • 对研究者疗效评分进行定期盲态中心反馈有助于提高肤色人群银屑病评估的一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Diverse racial and ethnic representation in clinical trials has been limited, not representative of the US population, and the subject of pending US Food and Drug Administration guidance. Psoriasis presentation and disease burden can vary by skin pigmentation, race and ethnicity, and socioeconomic differences. Overall, there are limited primary data on clinical response, genetics, and quality of life in populations with psoriasis and skin of color (SoC). The Varying Skin Tones in Body and Scalp Psoriasis: Guselkumab Efficacy and Safety trial (VISIBLE) is underway and uses strategies aimed at addressing this persistent gap. OBJECTIVE: To assess the innovative strategies used in the VISIBLE trial to recruit and retain diverse participants in a randomized clinical trial of psoriasis in participants with SoC. DESIGN, SETTING, AND PARTICIPANTS: This was an ad hoc quality improvement assessment of participant recruitment and retention approaches used by the VISIBLE trial. VISIBLE enrolled and randomized 211 participants (mean [SD] age, 43 [13] years; 75 females [36%] and 136 males [64%]) with SoC and moderate to severe plaque psoriasis from August 2022 to March 2023 to evaluate guselkumab treatment. The self-identified race and ethnicity of the participants was: 1 American Indian/Alaska Native (0.5%), 63 Asian (29.9%), 24 Black (11.4%), 94 Hispanic/Latino (44.5%), 13 Middle Eastern (6.2%), 1 Pacific Islander/Native Hawaiian (0.5%), 12 multiracial (5.7%), and 3 of other race and/or ethnicity (1.4%). Using a combination of objective (colorimetry to determine Fitzpatrick skin type) and self-reported (race and ethnicity consistent with SoC) parameters, VISIBLE sought to broaden inclusion of participants from various backgrounds. RESULTS: Observed improvements were that participant enrollment occurred approximately 7 times faster than anticipated (vs historical recruitment data for psoriasis studies); 211 participants (100%) self-identified themselves as a race or ethnicity other than White; and more than 50% had skin tone in the darker half of the Fitzpatrick skin type spectrum (type IV-VI). Innovations implemented by VISIBLE were (1) assessment of the natural history of postinflammatory pigment alteration and improvements over time using combined objective colorimetry and clinician- and patient-reported outcomes; (2) evaluation of genetic and comorbidity biomarkers relevant to participants with SoC; (3) a diverse demographic-driven approach to site selection (emphasizing investigator and staff diversity and experience with populations with SoC); (4) provision of cultural competency training to enhance participant enrollment and retention; (5) collection of patient-reported outcomes data in participants' primary language; and (6) periodic, blinded central review and feedback on investigator efficacy scoring to promote consistency and accuracy in evaluating psoriasis in participants with SoC. CONCLUSIONS AND RELEVANCE: VISIBLE is a unique study focused on addressing important knowledge and data gaps in populations of patients with psoriasis and SoC, with the goal of generating data to help improve clinical care and inform future best practices in diversity within dermatology research. The rapid study enrollment demonstrates that intentional and strategic approaches to clinical trial design and conduct can speed recruitment and bolster participation and retention of diverse populations in a dermatologic setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05272150.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Alexis A, McMichael A, Vashi N, et al. Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement. JAMA Dermatol. 2025. PMID: 39661358. doi:10.1001/jamadermatol.2024.5103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。